Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
BioMarin Pharmaceuticals, Inc. (NQ: BMRN)
57.21 USD  UNCHANGED
Official Closing Price  /  Updated: 4:00 PM EDT, Jun 19, 2013  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 0
Open 58.30
Bid (Size) 37.01 (100)
Ask (Size) 60.00 (1000)
Prev. Close 57.21
Today's Range 57.16 - 58.60
52wk Range 35.99 - 71.56
Shares Outstanding 139,010,175
Dividend Yield N/A
Featured News
More News
Get out of junk stocks now
March 22, 2013
Because the Federal Reserve’s easy-money policies won’t continue indefinitely, investors might want to begin reducing their holdings of low-quality stocks — which will be among the biggest casualties... Read More
category Retail , Opinion , KO , and 11 more.
from MarketWatch
Celgene Among Healthcare's Biggest Movers on January 2, 2013
January 02, 2013
The market is having a good day so far: the Nasdaq has risen 2.3%; the S&P 500 is up 1.8%; and the Dow has climbed 1.9%. The healthcare sector is the category of stocks relating to medical and healthc... Read More
from Investopedia Advisor Commentary

Featured News
Read More
Celgene and More Big Movers in Healthcare on December 10, 2012
December 10, 2012
from Investopedia Advisor Commentary
Canaccord Genuity on Apple, BioMarin, and Tesla
November 06, 2012
from Minyanville Headlines
Stock Downgrades: Energizer in Need of New Batteries
November 06, 2012
from Minyanville Headlines
Midday Nasdaq Rises Slightly Before Election Day
November 05, 2012
from Minyanville Headlines
BioMarin shares up 30% on treatment result
November 05, 2012
category Earnings , Biotechnology , Company Announcements/Warnings , and 17 more.
from MarketWatch
The Nasdaq Now: Up 15% Last Week, Research In Motion Continues Upward Climb
November 05, 2012
from Minyanville Headlines
More News
Read More
CORRECTED-UPDATE 1-Niche drugmaker ViroPharma attracts takeover interest - sources
June 19, 2013
category companyNews
from Reuters: Company News
UPDATE 1-Niche drugmaker ViroPharma attracts takeover interest -sources
June 17, 2013
category companyNews
from Reuters: Company News
Orphan drugmaker ViroPharma attracts takeover interest -sources
June 17, 2013
category companyNews
from Reuters: Company News
StockCall Study on BMRN, DCTH, ASTX, and AKRX
June 14, 2013
from ACCESSWIRE
Ongoing Clinical Trials Reveal Groundbreaking Results - Research Report on Alexion, BioMarin, Onyx, Questcor, and ImmunoGen
June 14, 2013
from PR Newswire
UPDATE: Jean-Jacques Bienaime, CEO of BioMarin, to Present at the Goldman Sachs Global Healthcare Conference
June 06, 2013
from GlobeNewswire News Releases
BioMarin to Present at the Goldman Sachs Global Healthcare Conference
June 06, 2013
from GlobeNewswire News Releases
Critical Alerts For General Motors, SAP, Blackberry, BioMarin Pharmaceutical, and Trimble Navigation Released By InvestorsObserver
June 05, 2013
from PR Newswire
BioMarin Initiates Phase 3 Trial for PEG-PAL for the Treatment of PKU
June 05, 2013
from GlobeNewswire News Releases
Upgrade Alert for BioMarin Pharmaceutical (BMRN)
June 04, 2013
from Comtex SmarTrend® News Briefs
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here

WHAT'S POPULAR IN THE VILLE

1
The QE Carry Trade Is Imploding Right Under Everyone's Noses
Vince Foster
2
The Future of Android Looks More Like Apple Inc.
Mike Schuster
3
Immunotherapy: Four Companies on the Verge of Cancer-Treatment Breakthroughs
TM Meyer
4
The Waning Integrity of US Financial Markets
Todd Harrison
5
Tech News: Tesla Motors Inc's First Recall Is a Display of Public Relations Prowess
Josh Wolonick